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Abstract
Background: Long-term homologous and temporary heterologous protection from dengue virus (DENV) infection may be
mediated by neutralizing antibodies. However, neutralizing antibody titers (NTs) have not been clearly associated with
protection from infection.
Methodology/Principal Findings: Data from two geographic cluster studies conducted in Kamphaeng Phet, Thailand were
used for this analysis. In the first study (2004–2007), cluster investigations of 100-meter radius were triggered by DENV-
infected index cases from a concurrent prospective cohort. Subjects between 6 months and 15 years old were evaluated for
DENV infection at days 0 and 15 by DENV PCR and IgM ELISA. In the second study (2009–2012), clusters of 200-meter radius
were triggered by DENV-infected index cases admitted to the provincial hospital. Subjects of any age $6 months were
evaluated for DENV infection at days 0 and 14. In both studies, subjects who were DENV PCR positive at day 14/15 were
considered to have been ‘‘susceptible’’ on day 0. Comparison subjects from houses in which someone had documented
DENV infection, but the subject remained DENV negative at days 0 and 14/15, were considered ‘‘non-susceptible.’’ Day 0
samples were presumed to be from just before virus exposure, and underwent plaque reduction neutralization testing
(PRNT). Seventeen ‘‘susceptible’’ (six DENV-1, five DENV-2, and six DENV-4), and 32 ‘‘non-susceptible’’ (13 exposed to DENV-
1, 10 DENV-2, and 9 DENV-4) subjects were evaluated. Comparing subjects exposed to the same serotype, receiver
operating characteristic (ROC) curves identified homotypic PRNT titers of 11, 323 and 16 for DENV-1, -2 and -4, respectively,
to differentiate ‘‘susceptible’’ from ‘‘non-susceptible’’ subjects.
Conclusions/Significance: PRNT titers were associated with protection from infection by DENV-1, -2 and -4. Protective NTs
appeared to be serotype-dependent and may be higher for DENV-2 than other serotypes. These findings are relevant for
both dengue epidemiology studies and vaccine development efforts.
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Introduction
Dengue is caused by four closely related, but antigenically
distinct dengue virus serotypes (DENV-1, -2, -3, -4) from the genus
Flavivirus in the family Flaviviridae [1,2]. In recent decades,
dengue has expanded in tropical and subtropical regions and
become one of the most prevalent vector-borne diseases of humans
with approximately 2.5 billion people living with risk of infection.
The annual global burden of dengue has been estimated to be 390
million infections with 96 million symptomatic cases [3]. Recently,
the first human efficacy trial of a dengue vaccine candidate was
completed in Thailand showing good neutralizing antibody
response to all four DENV serotypes after vaccination, but no
clinical efficacy against DENV-2 infection [4]. The relevance of
DENV neutralizing antibodies for protection or modulation of
DENV infection, therefore, remains unclear.
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A primary infection with one serotype is thought to produce
long-term protective immunity to re-infection with the homolo-
gous serotype. After a limited period of cross-protection, individ-
uals who have had a primary DENV infection are susceptible to
infection and disease by heterologous serotypes [5,6]. In human
challenge studies conducted by Sabin [7] in which DENV naı¨ve
individuals were infected with DENV-1 or DENV-2 and re-
challenged with homologous or heterologous virus at different
times after the initial challenge, protection against disease was
observed for at least 18 months against the homologous serotype
and at least 2 months against the heterologous serotype. Sabin also
noted that infection appeared to be milder if heterologous re-
challenge was performed up to 9 months after initial infection
suggesting a period of partial heterologous protection. Epidemi-
ological studies of dengue in endemic countries are consistent with
this pattern of susceptibility [8]. Mathematical modeling of 38
years of dengue cases admitted to a pediatric hospital in Bangkok,
Thailand, was consistent with approximately two years of
heterologous protection against disease [9]. Analyses of symptom-
atic and subclinical DENV infections from prospective cohorts in
Thailand and Nicaragua suggested a similar duration of cross-
protection against disease [10,11].
Heterologous protection is thought to be at least partly
mediated by temporary cross-protective neutralizing antibodies
from earlier infections [12]. Some studies have shown an
association between pre-existing neutralizing antibody titers
(NTs) and subsequent disease severity under certain conditions
[13,14,15]. Endy et al. found such a correlation between
homotypic NTs and subsequent viremia levels and disease severity
for DENV-3, but not for DENV-1 and DENV-2 in a Thai
pediatric cohort [14]. In contrast, Sirivichayakul et al. found no
relationship between homotypic NTs and subsequent infection by
DENV-1 or DENV-4 [16]. Up to now, no epidemiological study
in humans has been able to demonstrate an association between
pre-existing NTs and protection from infection.
One limitation of earlier prospective cohort studies has been
that they measured neutralizing antibodies up to one year prior to
infection. Neutralizing antibodies (and especially cross-reactive
antibodies) decrease substantially over time, however, and their
kinetics can be quite variable depending on factors such as DENV
serotype from previous and current infection, disease severity, host
genetics and immunological status [17]. Because neutralizing
antibody status just before virus exposure is likely the most relevant
for protection from infection, we sought to test the hypothesis that
neutralizing antibody titers immediately before exposure was
associated with the probability of infection by utilizing data from
geographic cluster studies in which high DENV transmission
activity has been demonstrated [18]. We showed an association
between homotypic NTs and the likelihood of subsequent
infection with DENV-1, -2 and -4.
Methods
Ethics Statement
Data from two different geographic cluster studies were used in
the current analysis. The first study (called ‘‘KPSII’’) was approved
by the Institutional Review Boards (IRBs) of the Thai Ministry of
Public Health (MOPH), Walter Reed Army Institute of Research
(WRAIR), University of Massachusetts Medical School (UMMS),
University of California at Davis (UCD), and San Diego State
University (SDSU). The second study (called ‘‘DEVOL’’) was
approved by the IRBs of the Thai MOPH, WRAIR, UCD, and
the State University of New York (SUNY) Upstate Medical
University. Written informed consent was obtained from adult
subjects (age $18 years) or the parents/guardians of child subjects
(age,18 years); assent was obtained from child subjects$7 and,
18 years of age.
KPSII Study
In the current study, we used data from a prospective
longitudinal cohort and geographic cluster study conducted from
2004 to 2007 among children living in Muang district, Kamphaeng
Phet province (KPP) in north-central Thailand. The study
methodology has been described previously [18,19,20]. Briefly,
geographic cluster investigations were initiated by ‘‘index’’ cases
from a longitudinal cohort of approximately 2,000 primary school
children. Active school absence-based surveillance was used to
detect symptomatic DENV infections in the cohort from June to
November of each study year. Cohort children who were DENV
positive by hemi-nested reverse transcriptase polymerase chain
reaction (PCR) [21,22] from an acute serum sample drawn within
three days of illness onset served as an index case to initiate a
positive cluster investigation around the index case house. Cohort
children who were DENV PCR negative from an acute illness
sample served as an index case for a negative cluster investigation.
In each geographic cluster, ten to 25 contact subjects aged six
months to 15 years living within 100 meters of the index case were
enrolled regardless of clinical status. Contact subjects were
evaluated at days 0 (i.e., same day as cluster initiation), 5, 10, and
15 by temperature measurement and symptom questionnaire.
Serum samples were collected on days 0 and 15. Paired day 0 and
15 samples underwent DENV nested PCR and an in-house
DENV/Japanese encephalitis virus (JEV) IgM capture enzyme-
linked immunosorbent assay (ELISA) [23].
DEVOL Study
We also used data from a geographic cluster study conducted
from 2009 to 2012 in the same district of KPP, Thailand. The
study methodology is being submitted in a separate manuscript. In
the DEVOL study, geographic cluster investigations were initiated
by ‘‘index’’ cases admitted to KPP hospital who were DENV
positive by nested PCR [21,22]. In each geographic cluster, adults
and children $6 months of age living within 200 meters of the
index case were enrolled regardless of clinical status. The distance
was increased compared to the KPSII study to attempt to capture
more DENV infections. Only individuals from households where
at least one member had a history of fever in the previous seven
days were considered for enrollment. Contact subjects were
Author Summary
Dengue is caused by four different dengue virus serotypes
(DENV-1, -2, -3, -4). Infection induces long-term protection
against the same serotype, but only short-term protection,
and possible enhancement, from different serotypes. DENV
neutralizing antibody titers (NTs) are thought to mediate
protection or modify disease. Association of NTs with
protection from infection has not, however, been clearly
demonstrated. We analyzed data from two geographic
clusters studies conducted in Kamphaeng Phet, Thailand,
in which DENV NTs just before virus exposure were
compared between DENV-infected ‘‘susceptible’’ and non-
infected ‘‘non-susceptible’’ subjects. NTs appeared to be
associated with protection against DENV-1, -2, and -4, but
at different NT cutoff levels, with the cutoff for DENV-2
appearing to be the highest. These findings are relevant
for ongoing efforts to investigate dengue epidemiology
and develop dengue vaccine candidates.
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evaluated at days 0 (i.e., same day as cluster initiation) and 14 by
temperature measurement, symptom questionnaire, and blood
collection. Day 0 samples were tested by DENV nested PCR; day
14 samples were tested using DENV Detect NS1 ELISA (InBios,
Seattle, Washington, USA) and, if positive, confirmed by DENV
nested PCR. Paired day 0 and 14 samples were tested by an in-
house DENV/JEV IgM capture ELISA [23].
Selection of ‘‘Susceptible’’ and ‘‘Non-susceptible’’
Subjects
In order to assess neutralizing antibody status just prior to virus
exposure, we first identified contact subjects from the two
geographic cluster studies who were DENV positive by nested
PCR at day 15 (KPSII study) or day 14 (DEVOL study). In the
DEVOL study, only clusters in which there was a DENV-2 index
case were utilized so that we could obtain data about DENV-2
which had not been detected at day 15 in the earlier KPSII study.
Day 14/15 PCR positive subjects were classified as ‘‘susceptible’’
to DENV infection since they had confirmed infection. In order to
create a ‘‘non-susceptible’’ comparison group, we identified
contact subjects from the two studies who lived in the same house
as another subject who was DENV positive on day 0, but were
themselves DENV negative by nested PCR and IgM ELISA on
both days 0 and 15 (KPSII study), or by NS1 ELISA and IgM
ELISA on both days 0 and 14 (DEVOL study). These DENV
negative ‘‘non-susceptible’’ subjects were presumed to have a high
likelihood of exposure to DENV during the cluster investigation,
yet still did not become infected. In KPSII, contact subjects who
met these criteria were selected to be in the ‘‘non-susceptible’’
group. In DEVOL, given the wider age range, each DENV-2
positive ‘‘susceptible’’ subject was matched with two ‘‘non-
susceptible’’ subjects by age (+/2 5 years), village and study year.
In both the KPSII and DEVOL studies, the exposure serotype for
all ‘‘non-susceptible’’ subjects was presumed to be the same as the
infecting serotype for the index case from the same cluster. In all
subjects, the day 0 blood sample was presumed to reflect the
neutralizing antibody status just prior to exposure or infection.
The number of DENV-3 infections from both the KPSII and
DEVOL studies was not sufficient to be evaluated.
Plaque Reduction Neutralization Test (PRNT)
To determine neutralizing antibody status just prior to exposure
for all ‘‘susceptible’’ and ‘‘non-susceptible’’ subjects, day 0 blood
samples were tested by an in-house plaque reduction neutraliza-
tion test (PRNT) using all four DENV serotypes and JEV as
previously described [24,25]. A monolayer of Macaca mulatta
kidney cells (LLC-MK2) was infected with 30–50 plaque-forming
units of DENV in the presence of four-fold serial dilutions of heat-
inactivated sample on a 12-well plate. For each dilution, the
number of virus plaques was counted and compared to the
number of plaques in a control where no sample was added.
Reference strains were as follows: DENV-1 (Thailand/16007/
1964), DENV-2 (Thailand/16681/1984), DENV-3 (Philippines/
16562/1964), DENV-4 (Indonesia/1036/1976) [KPSII samples],
DENV-4 (Thailand/C0036/2006) [DEVOL samples], and JEV
(SA-14-14 vaccine strain). In addition to the reference strains, day
0 samples from subjects from DENV-2 clusters (i.e., clusters where
the index case was infected with DENV-2) underwent PRNT
using DENV-2 strains from Thailand that were isolated at the
AFRIMS laboratory over a period of several decades as follows:
Asian-American 1982 (#D82-165), Asian I 1974 (#D74-066),
Asian I 1984 (#D84-501), Asian I 1994 (#D94-035), Asian I 2004
(#KDS00305), and homologous virus. Homologous viruses were
all Asian I genotype and were cultured either from the same blood
sample or from a subject from the same cluster or village in the
same year. This was done in order to evaluate possible differences
in PRNT titers against different DENV-2 strains given the lack of
vaccine efficacy against DENV-2 reported in a recent dengue
vaccine trial [4]. PRNT data was expressed as the reciprocal of the
dilution causing 50% plaque reduction (PRNT50) as extrapolated
from probit regression. In this study, our use of the terms
‘‘homotypic’’ and ‘‘heterotypic’’ neutralizing antibodies refers to
relationships between serotype neutralizing antibodies based solely
on the serotype-specific PRNT results along with the presumptive
serotype circulating within a geographic cluster.
Statistical Analysis
Analyses were performed comparing all subjects combined (i.e.,
‘‘susceptible’’ versus ‘‘non-susceptible’’ subjects), and by compar-
ing subjects according to exposure serotype. When comparing by
serotype, subjects with the same serotype came exclusively from
KPSII or DEVOL, but not both. Logistic regression models were
employed to test the hypothesis that pre-existing NTs were
associated with the probability of being PCR positive or negative.
For each test, the dependent variable was the infection status of the
subject. For each evaluated DENV strain used for PRNT, a simple
model with only the log of NT, and a model adjusted for age were
estimated. The model fit and predictive power were assessed for
each model using the Akaike Information Criterion (AIC) and the
area under receiver operating characteristic (ROC) curve (AUC).
The AIC provides a measure of how closely the models fit the
observed data, while penalizing for additional model complexity
[26]. Lower AIC values indicate better model fit. The ROC curve
is used to evaluate the accuracy of a diagnostic measure [27]. The
95% confidence interval (CI) of AUC was computed using 10,000
stratified bootstrap replicates [28]. Contingency tables were
created to illustrate the predictive ability of individual NT cutoff
values. The observed odds ratios were calculated and conditional
maximum likelihood estimates of the 95% CIs based on Fisher’s
exact test were estimated to show the uncertainty associated with
the observed odds ratios. All analyses were performed using the R
environment for statistical computing. ROC curves were created
and AUC was calculated using the pROC package for R [29].
Results
Of 1599 contact subjects from 50 positive and 53 negative
geographic cluster investigations in the KPSII study [18,30], 12
subjects were found to be DENV PCR positive at day 15 and,
therefore, considered to be ‘‘susceptible’’: six had DENV-1 and six
had DENV-4. All 12 subjects were PCR negative at day 0, and
DENV IgM ELISA negative at days 0 and 15. No data or blood
was collected after day 15. Twenty-two subjects from KPSII were
selected as ‘‘non-susceptible’’: 13 from DENV-1 clusters and nine
from DENV-4 clusters. The predominant circulating serotype
during the first two years of the KPSII study was DENV-4 and the
last two years was DENV-1 [19].
Of 740 contact subjects from 195 DENV-2 geographic cluster
investigations in the DEVOL study, five subjects were found to be
DENV-2 PCR positive at day 14 and, therefore, considered as
‘‘susceptible.’’ All five subjects were PCR negative at day 0, and
DENV IgM ELISA negative at days 0 and 14. No data or blood
was collected after day 14. Ten subjects were selected as ‘‘non-
susceptible’’ from DENV-2 clusters. The predominant circulating
serotype during all years of the DEVOL study was DENV-2
(unpublished data).
Altogether, 49 subjects were available for analysis: 17 PCR
positive ‘‘susceptible’’ subjects (six DENV-1, five DENV-2 and six
Dengue Neutralizing Antibodies and Protection
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DENV-4), and 32 PCR negative ‘‘non-susceptible’’ subjects (13
from DENV-1 clusters, 10 DENV-2 and 9 DENV-4). Table 1 lists
characteristics of the 49 subjects. Figures 1, 2 and 3 show bar
graphs of day 0 NTs for each subject. Seven ‘‘susceptible’’
compared with three ‘‘non-susceptible’’ subjects had DENV naı¨ve
NT profiles on day 0 (odds ratio = 6.460 [95% CI 1.198, 46.302]).
When all serotypes were combined, PCR status was significantly
associated with the log of homotypic NT both alone and adjusted
for age (Table 2). ROC curves were created for all serotypes
combined, and for each serotype separately (Figure 4). Consider-
ing subjects from just DENV-1 clusters, age-adjusted models to
predict PCR status were better (based on AIC and AUC) when
Figure 1. Pre-exposure neutralizing antibody titers (NTs) in dengue virus serotype 1 (DENV-1) ‘‘susceptible’’ and ‘‘non-susceptible
subjects. Graphs show: (a) six DENV-1 PCR positive (‘‘susceptible’’) subjects; (b) 13 DENV-1 PCR negative (‘‘non-susceptible’’) subjects. NTs for each
subject are against the reference strains for DENV-1, -2, -3, -4 and Japanese encephalitis virus (JEV) (red, blue, green, purple and orange, respectively).
doi:10.1371/journal.pntd.0003230.g001
Table 1. Characteristics of dengue PCR positive (‘‘susceptible’’) and negative (‘‘non-susceptible’’) subjects.
PCR positive (‘‘Susceptible’’) PCR negative (‘‘Non-susceptible’’)
DENV-1 clusters
Median age, yr (range) 9.7 (2.5–11.6) 5.0 (1.3–12.6)
Female/Male, no. 3/3 8/5
PRNT profile
DENV naı¨ve, no. 3 3
DENV monotypic, no. 1 4
DENV multitypic, no. 2 6
DENV-4 clusters
Median age, yr (range) 7.7 (2.0–13.2) 8.3 (1.7–13.0)
Female/Male, no. 4/2 4/5
PRNT profile
DENV naı¨ve, no. 3 0
DENV monotypic, no. 0 0
DENV multitypic, no. 3 9
DENV-2 clusters
Median age, yr (range) 29.8 (1.4–55.7) 30.5 (0.9–61.4)
Female/Male, no. 2/3 9/1
PRNT profile
DENV naı¨ve, no. 1 0
DENV monotypic, no. 1 2
DENV multitypic, no. 3 8
PRNT to a serotype was considered positive if serotype-specific titer $10. PCR = polymerase chain reaction; DENV = dengue virus; PRNT = plaque reduction
neutralization test; no significant differences are noted due to the small number of samples.
doi:10.1371/journal.pntd.0003230.t001
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using homotypic DENV-1 NTs (AUC=0.833 [95% CI 0.590,
1.000]) than heterotypic NTs (Table 3). For DENV-4 clusters,
age-adjusted models were better using homotypic DENV-4 NTs
(AUC=0.889 [95% CI 0.667, 1.000]) than heterotypic NTs
(Table 3). For DENV-2 clusters, age-adjusted models were better
using both homotypic DENV-2 reference NTs (AUC=0.740
[95% CI 0.460, 0.960]) and heterotypic DENV-4 reference NTs
(AUC=0.880 [95% CI 0.680, 1.000]) than other heterotypic NTs
(Table 3). When different DENV-2 strains were used for PRNT,
the AUC using Asian I 1974 strain appeared to have the best fit.
The AUC using DENV-2 homologous virus was comparable to
that using DENV-2 reference strain.
Homotypic reference strain NT cutoff values as determined by
ROC curves were used to create two-by-two contingency tables to
demonstrate the relationship between individual NT cutoffs and
PCR status (Table 4). Homotypic NT cutoff values were 11, 11, 16
and 323 for all serotypes combined, DENV-1, DENV-4, and
DENV-2, respectively. The observed odds ratio for each sample is
indicated and the 95% CI is presented to show the uncertainty
associated with this measure. These CIs should not be used to
assess statistical significance because they are post-hoc compari-
sons based on the cutoffs indicated by the ROC plot analysis. For
all serotypes combined, the observed odds ratio of becoming
infected (i.e., being PCR positive) if day 0 homotypic NT was $11
was 0.153 (95% CI 0.023, 0.700). For DENV-1 clusters, the
observed odds ratio if homotypic NT was$11 was 0 (95%CI 0.000,
1.554). For DENV-4 clusters, the observed odds ratio if homotypic
NT was $16 was 0 (95% CI 0.000, 0.842). For DENV-2, the odds
ratio if homotypic NT was $323 was 0 (95% CI 0.000, 1.279).
Discussion
Our analysis of subjects from geographic cluster studies
indicates that pre-existing homotypic neutralizing antibody titers
as measured by PRNT were positively associated with protection
against infection by DENV-1, -2 and -4; a similar analysis could
not be performed for DENV-3 because too few cases were
available. Homotypic NTs were more strongly associated with
protection than heterotypic NTs except in the case of DENV-2
infections, in which pre-existing heterotypic DENV-4 NTs were
also positively associated with protection against DENV-2. This is
the first human epidemiological study to report such an association
and provides some support for the use of PRNT titers as a
correlate of protective immunity in dengue epidemiology studies
and vaccine development efforts.
Two major strengths of this study design likely explain why a
significant association between NTs and protection from infection
was observed in contrast to previous prospective cohort studies.
Whereas earlier cohort studies typically analyzed NTs in blood
samples collected up to six months or more prior to the incident
DENV infection, our study provided blood samples from within
two weeks prior to virus exposure, thus minimizing the confound-
ing factor of variations in antibody kinetics. Although we could not
document the exact day of virus inoculation in ‘‘susceptible’’
subjects, the two week interval was likely sufficient to ensure that day
0 blood collections occurred before exposure. This presumption is
further supported by the fact that DENV IgM ELISA was negative
at day 14/15 indicating that infection was still early in its course.
Although we were able to confirm infection in ‘‘susceptible’’ subjects
by a positive PCR, we could not prove exposure in PCR negative
subjects. By requiring documentation of a DENV infection in the
same house, however, our selection criteria for ‘‘non-susceptible’’
subjects maximized the likelihood of such exposure. Previous results
from our cluster studies indicate a very high likelihood of virus
exposure in houses with known DENV infection [18]. We have
reported average DENV infection rates of greater than 30% over
two weeks in houses with known DENV infection pointing to even
higher rates of virus exposure if individuals who are exposed but
immunologically protected are taken into account. These exposure
rates are as high as is reasonably feasible in the natural setting (i.e.,
outside of an experimental challenge).
Whereas relatively low homotypic NT cutoff values were
associated with protection against DENV-1 and DENV-4 in this
study, much higher homotypic NT cutoffs were associated with
protection against DENV-2. This indicates that protective NTs
may depend, in part, on infecting serotype, with DENV-2 possibly
requiring substantially higher PRNT titers. This finding needs to
be tempered by the uncertainty in the mix of functional and non-
functional antibody subpopulations that are being measured by
PRNT, which could affect the generalizability of these NT cutoff
values to other populations. Furthermore, although age was
incorporated into the statistical analyses, the inclusion of adults in
Figure 2. Pre-exposure neutralizing antibody titers (NTs) in dengue virus serotype 4 (DENV-4) ‘‘susceptible’’ and ‘‘non-susceptible’’
subjects. Graphs show: (a) six DENV-4 PCR positive (‘‘susceptible’’) subjects; (b) nine DENV-4 PCR negative (‘‘non-susceptible’’) subjects. NTs for each
subject are against the reference strains for DENV-1, -2, -3, -4 and Japanese encephalitis virus (JEV) (red, blue, green, purple and orange, respectively).
doi:10.1371/journal.pntd.0003230.g002
Dengue Neutralizing Antibodies and Protection
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Figure 3. Pre-exposure neutralizing antibody titers (NTs) in dengue virus serotype 2 (DENV-2) ‘‘susceptible’’ and ‘‘non-susceptible’’
subjects. Each row shows one PCR positive (‘‘susceptible’’) subject and two matched PCR negative (‘‘non-susceptible’’) subjects. NTs for each subject
are against (in order from left to right for each subject) the reference strains for DENV-1, -2, -3, -4 and Japanese encephalitis virus (JEV), and six
different DENV-2 strains (Asian-American 1982 [#D82-165], Asian I 1974 [#D74-066], Asian I 1984 [#D84-501], Asian I 1994 [#D94-035], Asian I 2004
[#KDS00305]), and homologous DENV-2 Asian I strains).
doi:10.1371/journal.pntd.0003230.g003
Table 2. Logistic regression analysis of the relationship between homotypic neutralizing antibody titers and dengue PCR status.a
Parameter Estimate Standard error Z value P value
Model using log(homotypic NT) only
Intercept 20.011 0.382 20.028 0.978
Log(homotypic reference strain NT) 20.779 0.338 22.303 0.021
Model using log(homotypic NT) and age
Intercept 22.431 1.164 22.088 0.037
Log(homotypic reference strain NT) 21.549 0.524 22.955 0.003
Log(age+1) 2.982 1.328 2.245 0.024
aAnalysis combines all serotypes: 49 total subjects (17 PCR positive, 32 PCR negative).
PCR = polymerase chain reaction; NT = neutralizing antibody titer.
doi:10.1371/journal.pntd.0003230.t002
Dengue Neutralizing Antibodies and Protection
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the DEVOL study compared to only children in the KPSII study
could have introduced an additional confounding factor in
interpreting NT values. Individual PRNT titers necessary for
protection may, therefore, be difficult to define precisely. This
difficulty could be compounded by the inherent variability in
biological assays such as PRNT whether using similar or different
methods (e.g., different cell lines) [25]. Nevertheless, our findings
highlight the likelihood that traditionally accepted NT ranges for
vaccine immunogenicity may not necessarily be relevant for
protection from a natural DENV challenge. The lack of clinical
efficacy against DENV-2 in the recent dengue vaccine trial in
Thailand [4] may have partly been due to insufficiently high
DENV-2 NTs. Moreover, vaccination in a primed population with
the potential for interference from existing immunity makes this
situation even more complex. What may be a protective NT level
after natural DENV infection may not apply in the setting of
multivalent vaccination, especially in DENV primed individuals.
Although our study indicates that PRNT titers may be related to
protection from infection, these titers are likely to be surrogates for
other immune responses that are more directly relevant to
protection. For example, PRNT titers measured in Fc gamma
receptor-bearing cells [31,32] or after depletion of cross-reactive
Figure 4. Receiver operating characteristic (ROC) curves for homotypic neutralizing antibody titers (NTs) against reference strains.
Curves discriminate between dengue virus (DENV) PCR positive and negative subjects for: (a) all serotypes combined; (b) DENV-1; (c) DENV-4; (d)
DENV-2.
doi:10.1371/journal.pntd.0003230.g004
Dengue Neutralizing Antibodies and Protection
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antibodies [33], and quaternary E-protein domain I/II hinge
region antibody titers [34] have been proposed to be better
indicators of protection. Conversely, E-protein domain II fusion
loop antibodies have been proposed to function as cross-protective
antibodies within the pool of heterotypic neutralizing antibodies
[35]. High frequencies of circulating DENV-specific T lymphocyte
responses have also been proposed to provide some measure of
protective immunity [36,37]. Whatever measure is used will need
to be validated with well characterized samples from studies with
clinically relevant outcomes. In our study, it is interesting that
PRNT using homologous DENV-2 strains did not strengthen the
association with protection as compared with PRNT using
DENV-2 reference strain. Furthermore, using an altogether
different DENV-2 genotype (e.g., Asian-American) from the
infecting Asian I genotype did not weaken the association. These
results suggest that strain differences in PRNT may be of little
importance in assessing protection. Other more functionally
relevant assays may still be able to detect clinically relevant
strain-related differences.
Although the samples in our study were unique and informative,
the number that met testing criteria was small, limiting the power
of our analysis. Nevertheless, the fact that significant associations
were found despite these small numbers supports the strength of
the relationships. Larger sample numbers may have revealed more
subtle associations, for example, between different heterotypic NT
combinations and protection from infection. Because of the small
numbers, we used data from two different geographic cluster
studies over multiple years. The inclusion of both adults and
children with likely differing immunological backgrounds may
have affected our findings for the DENV-2 analysis, possibly
accounting for the higher DENV-2 NTs associated with protec-
tion. We also found that ‘‘susceptible’’ subjects were more likely to
be DENV NT naı¨ve than ‘‘non-susceptible’’ subjects. Thus, part of
the increased likelihood of infection associated with lower baseline
NTs may have been due to susceptibility to primary versus
secondary infections. In addition, as mentioned earlier, we could
not be certain that ‘‘non-susceptible’’ subjects had, in fact,
been exposed to DENV infection. If, however, some of the
Table 3. Comparison of logistic regression models of neutralizing antibody titers to predict dengue PCR status.
PRNT strain NT only Age-adjusted model
AIC AUC (95% CI) AIC AUC (95% CI)
All serotypes combineda
Homotypic reference 60.646 0.705 (0.570,0.828) 56.642 0.791 (0.659,0.906)
DENV-1b
DENV-1 reference 24.870 0.686 (0.487,0.846) 22.738 0.833 (0.590,1.000)
DENV-2 reference 24.813 0.699 (0.468,0.885) 25.636 0.782 (0.539,0.974)
DENV-3 reference 27.673 0.487 (0.269,0.731) 28.339 0.667 (0.372,0.923)
DENV-4 reference 25.170 0.615 (0.500,0.731) 25.188 0.782 (0.539,0.974)
JEV reference 27.614 0.474 (0.192,0.756) 28.561 0.667 (0.385,0.923)
DENV-4c
DENV-1 reference 22.540 0.704 (0.417,0.944) 24.398 0.704 (0.389,0.982)
DENV-2 reference 22.316 0.694 (0.389,0.944) 23.913 0.722 (0.407,0.944)
DENV-3 reference 19.625 0.722 (0.407,0.982) 21.639 0.722 (0.389,0.982)
DENV-4 reference 15.457 0.833 (0.667,1.000) 15.954 0.889 (0.667,1.000)
JEV reference 24.172 0.519 (0.232,0.815) 26.064 0.537 (0.241,0.852)
DENV-2d
DENV-1 reference 22.976 0.510 (0.180,0.840) 24.959 0.480 (0.140,0.840)
DENV-2 reference 22.270 0.720 (0.440,0.940) 22.708 0.740 (0.460,0.960)
DENV-3 reference 22.127 0.640 (0.310,0.920) 22.690 0.660 (0.340,0.920)
DENV-4 reference 20.949 0.750 (0.500,0.950) 20.759 0.880 (0.680,1.000)
JEV reference 22.087 0.660 (0.380,0.890) 23.957 0.660 (0.360,0.920)
DENV-2 Asian-Am 1982 22.195 0.760 (0.500,1.000) 22.291 0.780 (0.500,1.000)
DENV-2 Asian I 1974 20.196 0.760 (0.480,0.960) 17.863 0.880 (0.640,1.000)
DENV-2 Asian 1 1984 22.575 0.680 (0.400,0.920) 23.476 0.720 (0.420,0.940)
DENV-2 Asian I 1994 21.583 0.740 (0.480,0.940) 21.554 0.800 (0.520,0.980)
DENV-2 Asian I 2004 22.581 0.660 (0.370,0.900) 23.713 0.720 (0.420,0.960)
DENV-2 homologous 22.353 0.700 (0.420,0.930) 22.819 0.740 (0.440,0.960)
a49 subjects (17 PCR positive, 32 PCR negative);
b19 DENV-1 subjects (6 PCR positive, 13 PCR negative);
c15 DENV-4 subjects (6 PCR positive, 9 PCR negative);
d15 DENV-2 subjects (5 PCR positive, 10 PCR negative).
PCR = polymerase chain reaction; PRNT = plaque reduction neutralization test; NT = neutralizing antibody titer; AIC = Akaike Information Criterion; AUC = area under
receiver operating characteristic curve; CI = confidence interval; DENV = dengue virus; JEV = Japanese encephalitis virus.
Models using neutralizing antibody titer alone and adjusted for age are shown.
doi:10.1371/journal.pntd.0003230.t003
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‘‘non-susceptible’’ subjects had simply been unexposed rather
than protected from infection, the likelihood of detecting an
association between NT and protection would have been even
less. Finally, we were not able to characterize the clinical status of
infected subjects because no follow up visits took place after day
15. Therefore, we were unable to make conclusions about
associations with clinical severity which may be a more relevant
endpoint for vaccine evaluation than detection of viremia by
PCR.
In our study population, neutralizing antibody titers were
associated with protection against DENV-1, -2 and -4. NT levels
required for this protection varied for these three serotypes, but
were likely affected by the preceding epidemiological and
immunological history of the subjects. These findings will help
inform ongoing studies of dengue epidemiology and the develop-
ment of dengue vaccine candidates.
Supporting Information
Figure S1 Pre-exposure neutralizing antibody titers
(NTs) in dengue virus serotype 1 (DENV-1) ‘‘suscepti-
ble’’ and ‘‘non-susceptible subjects. (a) six DENV-1 PCR
positive (‘‘susceptible’’) subjects; (b) 13 DENV-1 PCR negative
(‘‘non-susceptible’’) subjects. NTs for each subject are against the
reference strains for DENV-1, -2, -3, -4 and Japanese encephalitis
virus (JEV) (red, blue, green, purple and orange, respectively).
(TIFF)
Figure S2 Pre-exposure neutralizing antibody titers
(NTs) in dengue virus serotype 4 (DENV-4) ‘‘susceptible’’
and ‘‘non-susceptible’’ subjects. (a) six DENV-4 PCR positive
(‘‘susceptible’’) subjects; (b) nine DENV-4 PCR negative (‘‘non-
susceptible’’) subjects. NTs for each subject are against the reference
strains for DENV-1, -2, -3, -4 and Japanese encephalitis virus (JEV)
(red, blue, green, purple and orange, respectively).
(TIFF)
Figure S3 Pre-exposure neutralizing antibody titers
(NTs) in dengue virus serotype 2 (DENV-2) ‘‘susceptible’’
and ‘‘non-susceptible’’ subjects. Each row shows one PCR
positive (‘‘susceptible’’) subject and two matched PCR negative
(‘‘non-susceptible’’) subjects. NTs for each subject are against (in
order from left to right for each subject) the reference strains for
DENV-1, -2, -3, -4 and Japanese encephalitis virus (JEV), and six
different DENV-2 strains (Asian-American 1982 [#D82-165],
Asian I 1974 [#D74-066], Asian I 1984 [#D84-501], Asian I
1994 [#D94-035], Asian I 2004 [#KDS00305]), and homologous
DENV-2 Asian I strains).
(TIFF)
Figure S4 Receiver operating characteristic (ROC)
curves for homotypic neutralizing antibody titers (NTs)
against reference strains. Curves discriminate between
dengue virus (DENV) PCR positive and negative subjects for: (a)
all serotypes combined; (b) DENV-1; (c) DENV-4; (d) DENV-2.
(TIFF)
Table S1 Characteristics of dengue PCR positive (‘‘sus-
ceptible’’) and negative (‘‘non-susceptible’’) subjects.
(TIFF)
Table S2 Logistic regression analysis of the relation-
ship between homotypic neutralizing antibody titers and
dengue PCR status.a
(TIFF)
Table S3 Comparison of logistic regression models of
neutralizing antibody titers to predict dengue PCR
status. Models using neutralizing antibody titer alone
and adjusted for age.
(TIFF)
Table S4 Contingency tables showing relationship be-
tween homotypic neutralizing antibody titer cutoff
values and dengue PCR status.
(TIFF)
Checklist S1 STROBE checklist.
(PDF)
Table 4. Contingency tables showing relationship between homotypic neutralizing antibody titer cutoff values and dengue PCR
status.
NT cutoff statusa PCR negative, no. PCR positive, no. Observed odds ratiob (95% CI)
All serotypes combined
Homotypic NT ,11 13 14 0.153 (0.023,0.700)
Homotypic NT $11 19 3
DENV-1
DENV-1 NT ,11 7 6 0 (0.000,1.554)
DENV-1 NT $11 6 0
DENV-4
DENV-4 NT ,16 3 6 0 (0.000,0.842)
DENV-4 NT $16 6 0
DENV-2
DENV-2 NT ,323 4 5 0 (0.000,1.279)
DENV-2 NT $323 6 0
aNTs from PRNT using reference strains;
bObserved odds ratio of becoming infected with given serotype if homotypic NT is $ cutoff value.
Conditional maximum likelihood estimates of the odds ratio are given to show the uncertainty associated with these values. Due to the post hoc examination of these
cutoffs based on the ROC plot results, these intervals should not be used to assess statistical significance. PCR = polymerase chain reaction; NT = neutralizing antibody
titer; CI = confidence interval; DENV = dengue virus.
doi:10.1371/journal.pntd.0003230.t004
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